Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension

After taking Amozatan (AMS, amlodipine / rozanthin combination) in patients with essential hypertension, the percentage of patients who reached the mean systolic target blood pressure was evaluated

Inclusion Criteria:

• Patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or rosartan monotherapy
• In patients with stage 2 hypertension (SBP 160-179 mmHg), patients requiring a combination therapy to reach the target blood pressure
• Patients who were changed to amosartan while using other hypertensive agents

Exclusion Criteria:

• Patients with hypersensitivity to dihydropyridine derivatives of amosartan
• Women who are pregnant or who may be pregnant and breastfeeding
• Patients with severe hepatic dysfunction
• Patients with severe aortic stenosis
• Patients at risk of shock
• Patients participating in other clinical studies

Estimated total number of patients: 3,150 Estimated number of centers: 37